Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.

Hewish M, Martin SA, Elliott R, Cunningham D, Lord CJ, Ashworth A.

Br J Cancer. 2013 Mar 5;108(4):983-92. doi: 10.1038/bjc.2013.3. Epub 2013 Jan 29.

2.

DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1.

Martin SA, McCabe N, Mullarkey M, Cummins R, Burgess DJ, Nakabeppu Y, Oka S, Kay E, Lord CJ, Ashworth A.

Cancer Cell. 2010 Mar 16;17(3):235-48. doi: 10.1016/j.ccr.2009.12.046.

3.

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2.

Martin SA, McCarthy A, Barber LJ, Burgess DJ, Parry S, Lord CJ, Ashworth A.

EMBO Mol Med. 2009 Sep;1(6-7):323-37. doi: 10.1002/emmm.200900040.

4.

Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers.

Martin SA, Hewish M, Sims D, Lord CJ, Ashworth A.

Cancer Res. 2011 Mar 1;71(5):1836-48. doi: 10.1158/0008-5472.CAN-10-2836. Epub 2011 Jan 17.

5.

Interdependence of DNA mismatch repair proteins MLH1 and MSH2 in apoptosis in human colorectal carcinoma cell lines.

Hassen S, Ali AA, Kilaparty SP, Al-Anbaky QA, Majeed W, Boman BM, Fields JZ, Ali N.

Mol Cell Biochem. 2016 Jan;412(1-2):297-305. doi: 10.1007/s11010-015-2636-3. Epub 2016 Jan 4.

PMID:
26728996
6.

Rhabdomyosarcoma in patients with constitutional mismatch-repair-deficiency syndrome.

Kratz CP, Holter S, Etzler J, Lauten M, Pollett A, Niemeyer CM, Gallinger S, Wimmer K.

J Med Genet. 2009 Jun;46(6):418-20. doi: 10.1136/jmg.2008.064212. Epub 2009 Mar 16.

PMID:
19293170
7.

Tumor mismatch repair immunohistochemistry and DNA MLH1 methylation testing of patients with endometrial cancer diagnosed at age younger than 60 years optimizes triage for population-level germline mismatch repair gene mutation testing.

Buchanan DD, Tan YY, Walsh MD, Clendenning M, Metcalf AM, Ferguson K, Arnold ST, Thompson BA, Lose FA, Parsons MT, Walters RJ, Pearson SA, Cummings M, Oehler MK, Blomfield PB, Quinn MA, Kirk JA, Stewart CJ, Obermair A, Young JP, Webb PM, Spurdle AB.

J Clin Oncol. 2014 Jan 10;32(2):90-100. doi: 10.1200/JCO.2013.51.2129. Epub 2013 Dec 9.

9.

Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells.

Schwarz VA, Hornung R, Fedier A, Fehr MK, Walt H, Haller U, Fink D.

Br J Cancer. 2002 Apr 8;86(7):1130-5.

10.

Prevalence of mismatch repair-deficient crypt foci in Lynch syndrome: a pathological study.

Kloor M, Huth C, Voigt AY, Benner A, Schirmacher P, von Knebel Doeberitz M, Bläker H.

Lancet Oncol. 2012 Jun;13(6):598-606. doi: 10.1016/S1470-2045(12)70109-2. Epub 2012 May 1.

PMID:
22552011
11.

Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network.

Bindra RS, Glazer PM.

Cancer Lett. 2007 Jul 8;252(1):93-103. Epub 2007 Feb 1.

PMID:
17275176
12.

Resistance to topoisomerase poisons due to loss of DNA mismatch repair.

Fedier A, Schwarz VA, Walt H, Carpini RD, Haller U, Fink D.

Int J Cancer. 2001 Aug 15;93(4):571-6.

13.

Genetic and clinical determinants of constitutional mismatch repair deficiency syndrome: report from the constitutional mismatch repair deficiency consortium.

Bakry D, Aronson M, Durno C, Rimawi H, Farah R, Alharbi QK, Alharbi M, Shamvil A, Ben-Shachar S, Mistry M, Constantini S, Dvir R, Qaddoumi I, Gallinger S, Lerner-Ellis J, Pollett A, Stephens D, Kelies S, Chao E, Malkin D, Bouffet E, Hawkins C, Tabori U.

Eur J Cancer. 2014 Mar;50(5):987-96. doi: 10.1016/j.ejca.2013.12.005. Epub 2014 Jan 15.

PMID:
24440087
14.

Simplified identification of Lynch syndrome: a prospective, multicenter study.

Bonnet D, Selves J, Toulas C, Danjoux M, Duffas JP, Portier G, Kirzin S, Ghouti L, Carrère N, Suc B, Alric L, Barange K, Buscail L, Chaubard T, Imani K, Guimbaud R.

Dig Liver Dis. 2012 Jun;44(6):515-22. doi: 10.1016/j.dld.2011.12.020. Epub 2012 Apr 3.

PMID:
22480969
15.

Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors.

Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, Kwint MP, Hoogerbrugge N, Nagtegaal ID, Ligtenberg MJ.

Gastroenterology. 2014 Mar;146(3):643-646.e8. doi: 10.1053/j.gastro.2013.12.002. Epub 2013 Dec 10.

PMID:
24333619
16.

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

von Bueren AO, Bacolod MD, Hagel C, Heinimann K, Fedier A, Kordes U, Pietsch T, Koster J, Grotzer MA, Friedman HS, Marra G, Kool M, Rutkowski S.

Br J Cancer. 2012 Oct 9;107(8):1399-408. doi: 10.1038/bjc.2012.403. Epub 2012 Sep 13.

17.

MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells.

Park JM, Huang S, Tougeron D, Sinicrope FA.

PLoS One. 2013 May 28;8(5):e65369. doi: 10.1371/journal.pone.0065369. Print 2013.

18.

DNA mismatch repair proteins are required for efficient herpes simplex virus 1 replication.

Mohni KN, Mastrocola AS, Bai P, Weller SK, Heinen CD.

J Virol. 2011 Dec;85(23):12241-53. doi: 10.1128/JVI.05487-11. Epub 2011 Sep 28.

19.

An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.

Bailis JM, Gordon ML, Gurgel JL, Komor AC, Barton JK, Kirsch IR.

PLoS One. 2013 Oct 29;8(10):e78726. doi: 10.1371/journal.pone.0078726. eCollection 2013.

20.

The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma.

Stark AM, Doukas A, Hugo HH, Mehdorn HM.

Neurol Res. 2010 Oct;32(8):816-20. doi: 10.1179/016164110X12645013515052. Epub 2010 Mar 10.

PMID:
20223108

Supplemental Content

Support Center